DLin-KC2-DMA

Research use only, not for human use.

DLin-KC2-DMA is a cationic/ionizable lipid. Which is used for siRNA delivery.

DLin-KC2-DMA is a cationic/ionizable lipid. Which is used for siRNA delivery.

DLin-KC2-DMA (1, 5 μg; 72 h) effectively produces a significant siRNA-mediated GAPDH gene silencing in both macrophages and dendritic cells.DLin-KC2-DMA (24 h) exhibits high uptake into macrophages and dendritic cells.DLin-KC2-DMA efficiently promotes release of encapsulated siRNA into the cytosol following uptake via the endocytotic pathway.DLin-KC2-DMA displays almost no toxicity in primary APCs. Cell Cytotoxicity Assay Cell Line:Macrophages, dendritic cells Concentration:5 μg/mL (DLin-KC2-DMA contained-LNPs)Incubation Time:72 h Result:Displayed almost no toxicity.Western Blot Analysis Cell Line:Macrophages, dendritic cells Concentration:1, 5 μg Incubation Time:72 h Result:Exhibited significant GAPDH silencing of more than 60% at 1 μg and of 80% at 5 μg in macrophages.Significantly reduced GAPDH protein and exhibited the silencing effects of 83% at 5 μg.

DLin-KC2-DMA contained-LNP siRNA systems (5 mg/kg; i.v.; single) effectively silences target genes in APcs in vivo. Animal Model:Naive C57BL/6 mice.Dosage:3 or 5 mg/kg (DLin-KC2-DMA contained-LNPs) Administration: Intravenous injection; single.Result:Significantly reduced GAPDH production in peritoneal cavity macrophages and dendritic cells and in the spleen-derived APCs when at 5 mg/kg.

——

Others

Other Targets

Others

——

——

1190197-97-7

642.09

C43H79NO2

>98% (HPLC)

DMSO : 100 mg/mL (155.74 mM; Need ultrasonic);Ethanol : 50 mg/mL (77.87 mM; Need ultrasonic)

CN(CCC1OC(CCCCCCCC/C=C\C/C=C\CCCCC)(CCCCCCCC/C=C\C/C=C\CCCCC)OC1)C

——

(-20℃)

With Ice Pack

≥ 2 years